Scarica l'app Stockscreener
0.478
0.52%
-0.0025
Dopo l'orario di chiusura:
.47
-0.008
-1.67%
Precedente Chiudi:
$0.4805
Aprire:
$0.487
Volume 24 ore:
177.93K
Relative Volume:
0.24
Capitalizzazione di mercato:
$15.97M
Reddito:
-
Utile/perdita netta:
$-19.73M
Rapporto P/E:
-0.2305
EPS:
-2.0742
Flusso di cassa netto:
$-16.94M
1 W Prestazione:
+0.84%
1M Prestazione:
+6.22%
6M Prestazione:
-30.99%
1 anno Prestazione:
-31.98%
Intervallo 1D:
$0.44
$0.5123
Intervallo di 1 settimana:
$0.44
$0.5123
Portata 52W:
$0.281
$2.06
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
Nome
Pasithea Therapeutics Corp
Settore
Industria
Telefono
(702) 514-4174
Indirizzo
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
Compare KTTA vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
0.478 | 16.06M | 0 | -19.73M | -16.94M | -2.0742 |
VRTX
Vertex Pharmaceuticals Inc
|
515.55 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.93 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
987.84 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.00 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.51 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Pasithea Therapeutics Corp Borsa (KTTA) Ultime notizie
Pasithea Therapeutics Company Profile & Introduction - Moomoo
Pasithea Therapeutics Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Pasithea Therapeutics Corp. Q2 2026: Net loss $(5.27M), EPS $(0.16) — 10-Q Summary - TradingView
KTTA: Q2 2026 net loss rose to $5.27M as R&D spending surged; cash reserves at $45.7M - TradingView
Vivo Opportunity entities disclose 9.99% Pasithea Therapeutics (KTTA) holdings via warrants and stock - Stock Titan
Enterprise value to EBIT forward of Pasithea Therapeutics Corp. – NASDAQ:KTTAW - TradingView
Pasithea Therapeutics Corp expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Pasithea Therapeutics Corp. SEC Filing (Aug 7, 2026) - Stock Titan
Pasithea Therapeutics (KTTA) Edges Higher: Micro-Cap Biotech Approaches Key Resistance at $0.48Corrective Wave - dars.gov.et
Opaleye group (NASDAQ: KTTA) discloses 6.14% Pasithea Therapeutics ownership in 13G/A - stocktitan.net
Pasithea Therapeutics (NASDAQ: KTTA) sets virtual 2026 meeting and reverse split vote - Stock Titan
Pasithea Therapeutics Corp (KTTA) Cash Flow - TradingKey
Pasithea Therapeutics Corp (KTTA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pasithea Therapeutics Corp (KTTA) Institutional Confidence - TradingKey
Pasithea Therapeutics Corp (KTTA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
KTTA|Pasithea Therapeutics Corp|Price:0.452|Chg%:-0.003 - TradingKey
Pasithea Therapeutics Corp (KTTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Pasithea Therapeutics Corp (KTTA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Pasithea Therapeutics Corp (KTTA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pasithea Therapeutics Corp (KTTA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pasithea Therapeutics Corp. Revenue Breakdown – NASDAQ:KTTA - TradingView
KTTA|Pasithea Therapeutics Corp|Price:0.455|Chg%:-0.025 - TradingKey
Pasithea Therapeutics (KTTA) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Surprise Amid Revenue AbsenceAnnual Report - po-news-eg.net
Pasithea Therapeutics Corp. (KTTA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Pasithea Therapeutics Corp. (KTTA) stock price, news, quote and history - Yahoo Finance UK
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology Congress 2026 - Investing News Network
Pasithea Therapeutics (KTTA) Registration filing Summary - Quartr
Pasithea Therapeutics (KTTA) Proxy filing Summary - Quartr
Pasithea Therapeutics Announces ESMO 2026 Poster Presentation of Phase I PAS-004 Study in Advanced Solid Tumors - Quiver Quantitative
Pasithea Therapeutics Announces Presentation of PAS-004 - GlobeNewswire
Pasithea's PAS-004 Study of Advanced Solid Tumors Gets ESMO Poster Slot - Stock Titan
New Strong Buy Stocks for July 20th - Yahoo Finance
Kartik Krishnan Net Worth (2026) - GuruFocus
Pasithea Therapeutics (KTTA) Tests Support Zone as Modest Decline ContinuesWyckoff Upthrust - dars.gov.et
Pasithea Therapeutics (KTTA) Edges Lower as Stock Hovers Near Support ZoneTriangle Correction - dars.gov.et
Pasithea Therapeutics to present at B. Riley Mi... - Pluang
Pasithea management to meet investors at B. Riley health summit in Boston - Stock Titan
Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit - GlobeNewswire
Pasithea Therapeutics Corp. (KTTA) Q1 2026 Earnings: Narrowing Losses Surprise, But Stock Slips on Revenue AbsenceEstimate Dispersion - dars.gov.et
KTTA Q1 2026 Earnings: Shares Surge on Better-Than-Expected Loss and Operational ProgressRevenue Growth Outlook - dars.gov.et
Pasithea Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss Drives Stock SurgeTax Rate Impact - dars.gov.et
Coastlands holds 3.84M shares in Pasithea Therapeutics (KTTA) — 11.48% disclosed - Stock Titan
Pasithea Therapeutics Corp Warrant 2021-12.08.26 on Pasithea Therapeutics Financial Disclosures & SEC Filings - TradingView
Pasithea extends dose escalation for MEK inhibitor PAS-004 - Investing.com UK
Pasithea extends dose escalation for MEK inhibitor PAS-004 By Investing.com - Investing.com South Africa
Pasithea Therapeutics Corp. announced that its candidate drug Pas-4 demonstrated a favorable safety profile in clinical studies. - Bitget
Pasithea reports positive PAS-004 Phase 1 cancer data - grafa.com
Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion - Investing News Network
Pasithea says PAS-004 stayed tolerable in cancer patients as dosing widens - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Enterprise value to revenue forward of Pasithea Therapeutics Corp. – NASDAQ:KTTA - TradingView
Pasithea Therapeutics Corp Azioni (KTTA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Pasithea Therapeutics Corp Azioni (KTTA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| STEINMAN LAWRENCE | Director |
Nov 28 '25 |
Buy |
0.75 |
133,333 |
100,000 |
199,691 |
| Marques Tiago | Chief Executive Officer |
Nov 28 '25 |
Buy |
0.75 |
33,333 |
25,000 |
73,334 |
| Dumesnil Simon | Director |
Nov 28 '25 |
Buy |
0.75 |
33,333 |
25,000 |
35,833 |
1.80%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):